Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia

Sergio A. Giralt, Mukta Arora, John M. Goldman, Stephanie J. Lee, Richard Maziarz, Philip L. McCarthy, Kathleen A. Sobocinski, Mary M. Horowitz

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The discovery and approval of imatinib drastically changed the therapeutic algorithm for chronic myeloid leukaemia (CML). Imatinib is now considered the therapy of choice for patients with newly diagnosed CML, including those previously considered candidates for allogeneic haematopoietic cell transplantation (HCT). We compared numbers and types of allogeneic HCTs performed for CML in North America before and after the introduction of imatinib, and publication of the International Randomized Trial of Interferon and STI571 (IRIS) using transplants reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The number of HCTs for CML registered with the CIBMTR in 1998 was 617; 62% were performed in first chronic phase (CP1). Only 1% of patients had received imatinib prior to transplantation. In 2003, the number of HCTs reported was 223; 44% were performed in CP1 and 77% of patients received imatinib prior to transplantation. The introduction of imatinib therapy has had a profound impact on the use of allogeneic transplantation for CML, with a marked decrease in the number of transplants for CML and an accompanying decrease in the proportion done in CP1. Most patients now receive a trial of imatinib before proceeding to HCT.

Original languageEnglish (US)
Pages (from-to)461-467
Number of pages7
JournalBritish Journal of Haematology
Volume137
Issue number5
DOIs
StatePublished - Jun 2007

Fingerprint

Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hematopoietic Stem Cells
Transplants
Therapeutics
Transplantation
Bone Marrow
Imatinib Mesylate
Homologous Transplantation
North America
Research
Interferons
Publications

Keywords

  • Chronic myeloid leukaemia
  • Haematopoietic cell transplantation
  • Imatinib
  • IRIS
  • STI571

ASJC Scopus subject areas

  • Hematology

Cite this

Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. / Giralt, Sergio A.; Arora, Mukta; Goldman, John M.; Lee, Stephanie J.; Maziarz, Richard; McCarthy, Philip L.; Sobocinski, Kathleen A.; Horowitz, Mary M.

In: British Journal of Haematology, Vol. 137, No. 5, 06.2007, p. 461-467.

Research output: Contribution to journalArticle

Giralt, Sergio A. ; Arora, Mukta ; Goldman, John M. ; Lee, Stephanie J. ; Maziarz, Richard ; McCarthy, Philip L. ; Sobocinski, Kathleen A. ; Horowitz, Mary M. / Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. In: British Journal of Haematology. 2007 ; Vol. 137, No. 5. pp. 461-467.
@article{56f7f721ba224c6aa1363fe74410090b,
title = "Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia",
abstract = "The discovery and approval of imatinib drastically changed the therapeutic algorithm for chronic myeloid leukaemia (CML). Imatinib is now considered the therapy of choice for patients with newly diagnosed CML, including those previously considered candidates for allogeneic haematopoietic cell transplantation (HCT). We compared numbers and types of allogeneic HCTs performed for CML in North America before and after the introduction of imatinib, and publication of the International Randomized Trial of Interferon and STI571 (IRIS) using transplants reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The number of HCTs for CML registered with the CIBMTR in 1998 was 617; 62{\%} were performed in first chronic phase (CP1). Only 1{\%} of patients had received imatinib prior to transplantation. In 2003, the number of HCTs reported was 223; 44{\%} were performed in CP1 and 77{\%} of patients received imatinib prior to transplantation. The introduction of imatinib therapy has had a profound impact on the use of allogeneic transplantation for CML, with a marked decrease in the number of transplants for CML and an accompanying decrease in the proportion done in CP1. Most patients now receive a trial of imatinib before proceeding to HCT.",
keywords = "Chronic myeloid leukaemia, Haematopoietic cell transplantation, Imatinib, IRIS, STI571",
author = "Giralt, {Sergio A.} and Mukta Arora and Goldman, {John M.} and Lee, {Stephanie J.} and Richard Maziarz and McCarthy, {Philip L.} and Sobocinski, {Kathleen A.} and Horowitz, {Mary M.}",
year = "2007",
month = "6",
doi = "10.1111/j.1365-2141.2007.06582.x",
language = "English (US)",
volume = "137",
pages = "461--467",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia

AU - Giralt, Sergio A.

AU - Arora, Mukta

AU - Goldman, John M.

AU - Lee, Stephanie J.

AU - Maziarz, Richard

AU - McCarthy, Philip L.

AU - Sobocinski, Kathleen A.

AU - Horowitz, Mary M.

PY - 2007/6

Y1 - 2007/6

N2 - The discovery and approval of imatinib drastically changed the therapeutic algorithm for chronic myeloid leukaemia (CML). Imatinib is now considered the therapy of choice for patients with newly diagnosed CML, including those previously considered candidates for allogeneic haematopoietic cell transplantation (HCT). We compared numbers and types of allogeneic HCTs performed for CML in North America before and after the introduction of imatinib, and publication of the International Randomized Trial of Interferon and STI571 (IRIS) using transplants reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The number of HCTs for CML registered with the CIBMTR in 1998 was 617; 62% were performed in first chronic phase (CP1). Only 1% of patients had received imatinib prior to transplantation. In 2003, the number of HCTs reported was 223; 44% were performed in CP1 and 77% of patients received imatinib prior to transplantation. The introduction of imatinib therapy has had a profound impact on the use of allogeneic transplantation for CML, with a marked decrease in the number of transplants for CML and an accompanying decrease in the proportion done in CP1. Most patients now receive a trial of imatinib before proceeding to HCT.

AB - The discovery and approval of imatinib drastically changed the therapeutic algorithm for chronic myeloid leukaemia (CML). Imatinib is now considered the therapy of choice for patients with newly diagnosed CML, including those previously considered candidates for allogeneic haematopoietic cell transplantation (HCT). We compared numbers and types of allogeneic HCTs performed for CML in North America before and after the introduction of imatinib, and publication of the International Randomized Trial of Interferon and STI571 (IRIS) using transplants reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The number of HCTs for CML registered with the CIBMTR in 1998 was 617; 62% were performed in first chronic phase (CP1). Only 1% of patients had received imatinib prior to transplantation. In 2003, the number of HCTs reported was 223; 44% were performed in CP1 and 77% of patients received imatinib prior to transplantation. The introduction of imatinib therapy has had a profound impact on the use of allogeneic transplantation for CML, with a marked decrease in the number of transplants for CML and an accompanying decrease in the proportion done in CP1. Most patients now receive a trial of imatinib before proceeding to HCT.

KW - Chronic myeloid leukaemia

KW - Haematopoietic cell transplantation

KW - Imatinib

KW - IRIS

KW - STI571

UR - http://www.scopus.com/inward/record.url?scp=34247863611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247863611&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2007.06582.x

DO - 10.1111/j.1365-2141.2007.06582.x

M3 - Article

C2 - 17459051

AN - SCOPUS:34247863611

VL - 137

SP - 461

EP - 467

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -